Cargando…

PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report

BACKGROUND: Currently, the detection of PIK3CA mutations is of special interest in personalized medicine because it is frequently found in triple-negative breast cancer (TNBC). The PI3KCA mutation is an independent negative prognostic factor for survival in metastatic breast cancer, and its prognost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valencia, Guillermo Arturo, Rioja, Patricia, Morante, Zaida, Araujo, Jhajaira M, Vallejos, Heberth Daniel, Guerra, Henry, Gomez, Henry L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394163/ https://www.ncbi.nlm.nih.gov/pubmed/34513603 http://dx.doi.org/10.5306/wjco.v12.i8.702

Ejemplares similares

Immunotherapy in triple-negative breast cancer: A literature review and new advances
por: Valencia, Guillermo Arturo, et al.
Publicado: (2022)

A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease
por: Pinto, Joseph A, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer
por: de la Cruz-Ku, Gabriel, et al.
Publicado: (2020)

Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
por: Araujo, Jhajaira M., et al.
Publicado: (2018)

Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer
por: Morante, Zaida, et al.
Publicado: (2023)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients
por: Giannoni-Luza, Stefano, et al.
Publicado: (2022)

The current situation regarding the availability and accessibility of anticancer drugs for breast cancer in the Peruvian public health systems
por: Valencia-Mesías, Guillermo, et al.
Publicado: (2021)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
por: Cossu-Rocca, Paolo, et al.
Publicado: (2015)

Renal liposarcoma: case report and review of systemic treatment
por: Rioja, Patricia, et al.
Publicado: (2021)

Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes
por: Araujo, Jhajaira M., et al.
Publicado: (2022)

Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience
por: De-la-Cruz-Ku, Gabriel, et al.
Publicado: (2020)

Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
por: Pinto, Joseph A, et al.
Publicado: (2018)

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
por: Lehmann, Brian D, et al.
Publicado: (2014)

Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer
por: Araujo, Jhajaira M., et al.
Publicado: (2016)

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015)

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
por: Rabanal, Connie, et al.
Publicado: (2017)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
por: Jacot, William, et al.
Publicado: (2015)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
por: Fusco, Nicola, et al.
Publicado: (2021)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
por: Kodahl, Annette R., et al.
Publicado: (2018)

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer
por: Jouali, Farah, et al.
Publicado: (2018)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Association between PIK3CA Mutations in Blood and Tumor-Infiltrating Lymphocytes in Peruvian Breast Cancer Patients
por: Castaneda, Carlos A., et al.
Publicado: (2022)

Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression
por: Pesch, Andrea M., et al.
Publicado: (2022)

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
por: Kim, Seung Tae, et al.
Publicado: (2015)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

PIK3CA-mutations in breast cancer
por: Reinhardt, Kristin, et al.
Publicado: (2022)

Prognostic factors for early relapse in non-metastatic triple negative breast cancer — real world data
por: Soares, Rita Félix, et al.
Publicado: (2021)

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
por: Liedtke, Cornelia, et al.
Publicado: (2008)

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2021)

Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer
por: Cardinali, Barbara, et al.
Publicado: (2022)

Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006)

Initiating breast cancer by PIK3CA mutation
por: Miller, Todd W
Publicado: (2012)

PIK3CA Mutations in Hepatocellular Carcinoma in Korea
por: Kim, Heesue, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qqdqlq54t9b6vu6ls8i15foft2